BIOTRONIK Neuro has purchased a portfolio of intellectual property (IP) from Soin Neuroscience related to spinal cord stimulation (SCS) technology.
The patents obtained cover several areas, including SCS waveform design, adaptive programming, and the integration of machine learning and AI in neuromodulation therapy.
With a focus on chronic pain treatment, BIOTRONIK Neuro plans to use the IP as part of its efforts to develop a next-generation SCS programme.
Soin Neuroscience will remain independent after the deal. The agreement applies solely to the IP associated with the SCS programme; other research, clinical, and operational activities at the company will continue as usual.
The acquisition follows a previous research collaboration between the two companies in December 2025.
That project explored new waveforms and personalised spinal cord stimulation approaches using BIOTRONIK Neuro’s Prospera SCS system. This prior research formed the basis for the current agreement.
BIOTRONIK Neuro president Andreas Gute said: “Dr Soin and his team have consistently pushed the boundaries of what personalised stimulation can look like, and this IP is a strong complement to our own SCS platform.
“Bringing these patents into BIOTRONIK Neuro reflects the natural next step in our relationship and reinforces our commitment to advancing neuromodulation science for the benefit of patients living with chronic pain.”
The company added that the new IP will add data-driven, adaptive stimulation capabilities to its platform, which already features flexible programming and remote patient management.
Soin Neuroscience founder Dr Amol Soin said: “This is a proud moment not just for our company, but for Dayton and Ohio’s life sciences community. Innovation in medicine doesn’t have to come only from the coasts.
“We’ve built this technology here, and seeing it recognised by a company of BIOTRONIK’s calibre is validation of the work our team has put in over many years.”
Soin Neuroscience will continue to develop pain management and other medical technologies from its base in Dayton, Ohio.
